Analyst Price Target is $8.30
▲ +501.45% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Unicycive Therapeutics in the last 3 months. The average price target is $8.30, with a high forecast of $24.00 and a low forecast of $3.00. The average price target represents a 501.45% upside from the last price of $1.38.
Current Consensus is
Buy
The current consensus among 5 polled investment analysts is to buy stock in Unicycive Therapeutics. This Buy consensus rating has held steady for over two years.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Read More